You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMeloxicam
Accession NumberDB00814  (APRD00529)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionMeloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. In Europe it is marketed under the brand names Movalis, Melox, and Recoxa. In North America it is generally marketed under the brand name Mobic. In Latin America, the drug is marketed as Tenaron. [Wikipedia]
Structure
Thumb
Synonyms
Meloxicam
Méloxicam
Meloxicam
Meloxicamum
Mobic
UNII-vg2qf83cgl
External Identifiers
  • UH-AC62
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Meloxicamtablet15 mgoralActavis Pharma Company2004-08-12Not applicableCanada
Act Meloxicamtablet7.5 mgoralActavis Pharma Company2004-08-12Not applicableCanada
Auro-meloxicamtablet7.5 mgoralAuro Pharma Inc2012-10-19Not applicableCanada
Auro-meloxicamtablet15 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Ava-meloxicamtablet7.5 mgoralAvanstra Inc2011-11-082014-08-21Canada
Ava-meloxicamtablet15.0 mgoralAvanstra Inc2011-08-112014-08-21Canada
Dom-meloxicamtablet7.5 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-meloxicamtablet15 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Meloxicamtablet7.5 mgoralSanis Health Inc2010-07-26Not applicableCanada
Meloxicamsuspension7.5 mg/5mLoralRoxane Laboratories, Inc.2001-11-01Not applicableUs
Meloxicamtablet15 mgoralSanis Health Inc2010-07-26Not applicableCanada
Meloxicamtablet7.5 mgoralPro Doc Limitee2009-06-10Not applicableCanada
Meloxicamtablet7.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Meloxicamtablet15 mgoralPro Doc Limitee2009-06-10Not applicableCanada
Meloxicamtablet15 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Mobictablet7.5 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-06-01Not applicableUs
Mobictablet15 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2000-10-01Not applicableUs
Mobictablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2000-06-01Not applicableUs
Mobicsuspension7.5 mg/5mLoralBoehringer Ingelheim Pharmaceuticals, Inc.2005-11-01Not applicableUs
Mobicoxtablet7.5 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2000-09-26Not applicableCanada
Mobicoxtablet15 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2000-09-26Not applicableCanada
Mylan-meloxicamtablet7.5 mgoralMylan Pharmaceuticals Ulc2004-08-11Not applicableCanada
Mylan-meloxicamtablet15 mgoralMylan Pharmaceuticals Ulc2004-08-11Not applicableCanada
Nu-meloxicamtablet7.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-meloxicamtablet15.0 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-meloxicamtablet7.5 mgoralPharmel Inc2004-04-06Not applicableCanada
PHL-meloxicamtablet15 mgoralPharmel Inc2004-04-06Not applicableCanada
PMS-meloxicamtablet7.5 mgoralPharmascience Inc2003-11-07Not applicableCanada
PMS-meloxicamtablet15 mgoralPharmascience Inc2003-11-07Not applicableCanada
Ratio-meloxicamtablet7.5 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-11-112014-09-19Canada
Ratio-meloxicamtablet15 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-11-112014-09-19Canada
Teva-meloxicamtablet15 mgoralTeva Canada Limited2004-10-22Not applicableCanada
Teva-meloxicamtablet7.5 mgoralTeva Canada Limited2004-10-22Not applicableCanada
Vivlodexcapsule5 mg/1oralIroko Pharmaceuticals, LLC2015-10-31Not applicableUs
Vivlodexcapsule10 mg/1oralIroko Pharmaceuticals, LLC2015-10-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-meloxicamtablet15 mgoralApotex Inc2004-02-13Not applicableCanada
Apo-meloxicamtablet7.5 mgoralApotex Inc2004-02-13Not applicableCanada
Comfort Pac With MeloxicamkitPd Rx Pharmaceuticals, Inc.2013-07-09Not applicableUs
Comfort Pac With MeloxicamkitPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralProficient Rx LP2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMed Vantx, Inc.2006-10-02Not applicableUs
Meloxicamtablet15 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-07Not applicableUs
Meloxicamtablet15 mg/1oralUnichem Pharmaceuticals (USA), Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMedsource Pharmaceuticals2009-12-01Not applicableUs
Meloxicamtablet15 mg/1oralNorthwind Pharmaceuticals2014-04-02Not applicableUs
Meloxicamtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralTeva Pharmaceuticals USA Inc2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralApotex Corp2010-05-14Not applicableUs
Meloxicamtablet7.5 mg/1oralStrides Arcolab Limited2009-05-14Not applicableUs
Meloxicamtablet7.5 mg/1oralLupin Pharmaceuticals, Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralBlenheim Pharmacal, Inc.2014-02-19Not applicableUs
Meloxicamtablet7.5 mg/1oralMc Kesson Contract Packaging2011-12-23Not applicableUs
Meloxicamtablet7.5 mg/1oralSTAT Rx USA LLC2009-10-05Not applicableUs
Meloxicamtablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-17Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2011-08-15Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2011-09-08Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2015-01-02Not applicableUs
Meloxicamtablet15 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Meloxicamtablet7.5 mg/1oralBlenheim Pharmacal, Inc.2012-10-24Not applicableUs
Meloxicamtablet7.5 mg/1oralReady Meds2012-08-28Not applicableUs
Meloxicamtablet15 mg/1oralMed Vantx, Inc.2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralCipla USA Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Meloxicamtablet7.5 mg/1oralGlenmark Generics Inc., USA2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1Rebel Distributors Corp.2006-12-20Not applicableUs
Meloxicamtablet15 mg/1oralAv Kare, Inc.2014-09-192015-12-29Us
Meloxicamtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralUnit Dose Services2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralPhysicians Total Care, Inc.2006-08-07Not applicableUs
Meloxicamtablet7.5 mg/1oralMylan Pharmaceuticals Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralDIRECT RX2014-01-01Not applicableUs
Meloxicamtablet7.5 mg/1oralAurobindo Pharma Limited2006-10-02Not applicableUs
Meloxicamtablet7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralbryant ranch prepack2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralMed Vantx, Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Meloxicamtablet7.5 mg/1oralAidarex Pharmaceuticals LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2016-01-26Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-05-03Not applicableUs
Meloxicamtablet7.5 mg/1oralNorthwind Pharmaceuticals2015-01-05Not applicableUs
Meloxicamtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2009-07-01Not applicableUs
Meloxicamtablet15 mg/1oralTeva Pharmaceuticals USA Inc2006-07-20Not applicableUs
Meloxicamtablet7.5 mg/1oralCarlsbad Technology, Inc.2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralStrides Arcolab Limited2009-05-14Not applicableUs
Meloxicamtablet15 mg/1oralLupin Pharmaceuticals, Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
Meloxicamtablet7.5 mg/1oralAv Pak2012-10-09Not applicableUs
Meloxicamtablet15 mg/1oralInternational Laboratories, Inc.2008-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralDispensing Solutions, Inc.2009-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralSterling Knight Pharmaceuticals, Llc2015-12-23Not applicableUs
Meloxicamtablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-08-30Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2014-02-01Not applicableUs
Meloxicamtablet7.5 mg/1oralApotex Corp.2006-07-28Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2010-04-23Not applicableUs
Meloxicamtablet15 mg/1oralReady Meds2012-08-28Not applicableUs
Meloxicamtablet15 mg/1oralBelcher Pharmaceuticals,LLC2015-06-30Not applicableUs
Meloxicamtablet15 mg/1oralAurobindo Pharma Limited2006-10-02Not applicableUs
Meloxicamtablet15 mg/1oralGlenmark Generics Inc., USA2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralRebel Distributors Corp.2006-12-20Not applicableUs
Meloxicamtablet7.5 mg/1oralCardinal Health2010-06-022015-12-29Us
Meloxicamtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2012-08-28Not applicableUs
Meloxicamtablet7.5 mg/1oralMylan Institutional Inc.2006-08-01Not applicableUs
Meloxicamtablet7.5 mg/1oralCardinal Health2011-01-07Not applicableUs
Meloxicamtablet15 mg/1oralMylan Pharmaceuticals Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralbryant ranch prepack2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMed Vantx, Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Meloxicamtablet15 mg/1oralAidarex Pharmaceuticals LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-08-23Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Meloxicamtablet7.5 mg/1oralClinical Solutions Wholesale2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralKAISER FOUNDATION HOSPITALS2015-07-09Not applicableUs
Meloxicamtablet15 mg/1oralCarlsbad Technology, Inc.2010-06-30Not applicableUs
Meloxicamtablet7.5 mg/1oralCadila Healthcare Limited2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralSTAT Rx USA LLC2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralExelan Pharmaceuticals Inc.2015-04-14Not applicableUs
Meloxicamtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralAv Pak2012-10-09Not applicableUs
Meloxicamtablet7.5 mg/1oralInternational Laboratories, Inc.2008-12-01Not applicableUs
Meloxicamtablet7.5 mg/1oralReady Meds2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralDispensing Solutions, Inc.2009-12-01Not applicableUs
Meloxicamtablet15 mg/1oralSterling Knight Pharmaceuticals, Llc2010-06-30Not applicableUs
Meloxicamtablet7.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralREMEDYREPACK INC.2011-08-24Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Meloxicamtablet15 mg/1oralApotex Corp.2006-07-28Not applicableUs
Meloxicamtablet7.5 mg/1oralBlenheim Pharmacal, Inc.2010-04-13Not applicableUs
Meloxicamtablet7.5 mg/1oralProficient Rx LP2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralMed Vantx, Inc.2006-10-02Not applicableUs
Meloxicamtablet7.5 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-15Not applicableUs
Meloxicamtablet7.5 mg/1oralUnichem Pharmaceuticals (USA), Inc.2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralMylan Institutional Inc.2006-08-01Not applicableUs
Meloxicamtablet7.5 mg/1oralCardinal Health2006-07-01Not applicableUs
Meloxicamtablet7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-20Not applicableUs
Meloxicamtablet15 mg/1oralClinical Solutions Wholesale2007-03-07Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2011-09-02Not applicableUs
Meloxicamtablet7.5 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralMed Vantx, Inc.2010-10-14Not applicableUs
Meloxicamtablet7.5 mg/1oralCipla USA Inc.2006-07-19Not applicableUs
Meloxicamtablet7.5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2011-07-18Not applicableUs
Meloxicamtablet15 mg/1oralREMEDYREPACK INC.2013-08-212016-04-05Us
Meloxicamtablet7.5 mg/1oralUnit Dose Services2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralPhysicians Total Care, Inc.2006-08-07Not applicableUs
Meloxicamtablet15 mg/1oralKAISER FOUNDATION HOSPITALS2015-07-09Not applicableUs
Meloxicamtablet7.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Meloxicamtablet15 mg/1oralCadila Healthcare Limited2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralZydus Pharmaceuticals (USA) Inc.2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralSTAT Rx USA LLC2007-03-07Not applicableUs
Meloxicamtablet7.5 mg/1oralAv Kare, Inc.2014-09-192015-12-29Us
Meloxicamtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Meloxicamtablet15 mg/1oralBlenheim Pharmacal, Inc.2013-11-08Not applicableUs
Meloxicamtablet15 mg/1oralReady Meds2010-06-30Not applicableUs
Meloxicamtablet7.5 mg/1oralCarilion Materials Management2006-07-19Not applicableUs
Meloxicamtablet15 mg/1oralLife Line Home Care Services, Inc.2006-08-07Not applicableUs
Meloxicamtablet15 mg/1oralSTAT Rx USA LLC2009-10-05Not applicableUs
Meloxicamtablet7.5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Meloxicamtablet15 mg/1oralInternational Labs, Inc.2010-10-15Not applicableUs
Meloxicamtablet7.5 mg/1oralApotex Corp2010-05-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AchefreeAchefree
ActicamAcromax Dominicana
AflamidAnchor
AfloxxLusa
AglanZentiva
AinecoxCheminter
AldoronIvax
AlentumLafrancol
AlgiflexBiogen
AliviodolCentrum
AnaxicamCaferma
AnposelMedipharm
AntrendLabormed
AponipPharmatec
ArelogerGerard
AremilMagma
ArmexQintar Pharma
ArroxXepa-Soul Pattinson
ArsitecArsmedendi
ArtexPharmedic
ArthrobicMekophar
ArthroxPharmanel
ArticamStandpharm
ArtiproHelix
ArtricloxGarmisch
ArtrifilmG&R
ArtriflamSherfarma
ArtrilomPro.Med.CS
ArtriloxCombiphar
ArtroxPharmaBrand
AspicamBiofarm
AtiflamDoctor Andreu
AtrozanPharmstandard
AuroxicamAurora
AxiusHersil
Brand mixtures
NameLabellerIngredients
Trepoxicam-7.5Physician Therapeutics Llc
SaltsNot Available
Categories
UNIIVG2QF83CGL
CAS number71125-38-7
WeightAverage: 351.401
Monoisotopic: 351.034747299
Chemical FormulaC14H13N3O4S2
InChI KeyInChIKey=ZRVUJXDFFKFLMG-UHFFFAOYSA-N
InChI
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
IUPAC Name
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassNot Available
Direct ParentBenzothiazines
Alternative Parents
Substituents
  • N-arylamide
  • Benzothiazine
  • 2,5-disubstituted 1,3-thiazole
  • Benzenoid
  • Ortho-thiazine
  • Heteroaromatic compound
  • Vinylogous acid
  • Thiazole
  • Sulfonic acid derivative
  • Sulfonamide
  • Azole
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor symptomatic treatment of arthritis and osteoarthritis.
PharmacodynamicsMeloxicam is an nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Prostaglandins are substances that contribute to inflammation of joints. Meloxicam inhibits prostaglandin synthetase (cylooxygenase 1 and 2) and leads to a decrease of the synthesis of prostaglandins, therefore, inflammation is reduced.
Mechanism of actionAnti-inflammatory effects of meloxicam are believed to be due to inhibition of prostaglandin synthetase (cylooxygenase), leading to the inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis may be associated with the analgesic and antipyretic effects of meloxicam.
Related Articles
AbsorptionAbsolute bioavailability = 89%
Volume of distribution
  • 10 L
Protein binding99.4% bound, primarily to albumin
Metabolism

Meloxicam is almost completely metabolized into inactive metabolites by the cytochrome P450 (CYP450) isozymes. CYP2C9 is primarily responsible for metabolism of meloxicam while CYP3A4 plays a minor role. An intermediate metabolite, 5'-hydroxymethyl meloxicam, is further metabolized to 5'-carboxy meloxicam, the major metabolite. Peroxidase activity is thought to produce the two other inactive metabolites of meloxicam.

SubstrateEnzymesProduct
Meloxicam
Not Available
5'-carboxy meloxicamDetails
Meloxicam
Not Available
5'-hydroxymethyl meloxicamDetails
Route of eliminationMeloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.
Half life15-20 hours
Clearance
  • 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets]
  • 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules]
  • 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules]
  • 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules]
  • 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]
ToxicityLD50, Acute: 84 mg/kg (Rat); Oral 470 mg/kg (Mouse); Oral 320 mg/kg (Rabbit)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Meloxicam Action PathwayDrug actionSMP00106
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.9811
Caco-2 permeable+0.8484
P-glycoprotein substrateSubstrate0.5181
P-glycoprotein inhibitor INon-inhibitor0.7516
P-glycoprotein inhibitor IINon-inhibitor0.7491
Renal organic cation transporterNon-inhibitor0.9275
CYP450 2C9 substrateSubstrate0.5637
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.6649
CYP450 1A2 substrateNon-inhibitor0.9271
CYP450 2C9 inhibitorInhibitor0.5511
CYP450 2D6 inhibitorNon-inhibitor0.9322
CYP450 2C19 inhibitorNon-inhibitor0.8948
CYP450 3A4 inhibitorNon-inhibitor0.8191
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7316
Ames testNon AMES toxic0.8576
CarcinogenicityNon-carcinogens0.7052
BiodegradationNot ready biodegradable0.9312
Rat acute toxicity3.4619 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9579
hERG inhibition (predictor II)Non-inhibitor0.7999
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis totowa llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Beijing yabao biopharmaceutical co ltd
  • Breckenridge pharmaceutical inc
  • Caraco pharmaceutical laboratories ltd
  • Carlsbad technology inc
  • Corepharma llc
  • Dr reddys laboratories inc
  • Genpharm inc
  • Glenmark generics ltd
  • Lupin pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Strides arcolab ltd
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Unichem laboratories ltd
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral15.0 mg
Kit
Suspensionoral7.5 mg/5mL
Tablet7.5 mg/1
Tabletoral15 mg/1
Tabletoral7.5 mg/1
Tabletoral15 mg
Tabletoral7.5 mg
Kit
Capsuleoral10 mg/1
Capsuleoral5 mg/1
Prices
Unit descriptionCostUnit
Meloxicam 7.5 mg/5ml Suspension 100ml Bottle86.99USD bottle
Meloxicam bp powder56.61USD g
Mobic 15 mg tablet7.37USD tablet
Meloxicam 15 mg tablet4.94USD tablet
Mobic 7.5 mg tablet4.74USD tablet
Meloxicam 7.5 mg tablet3.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6184220 Yes1999-09-252019-09-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254 dec °CPhysProp
water solubility7.15 mg/LNot Available
logP3.43AVDEEF,A (1997)
Caco2 permeability-4.71ADME Research, USCD
pKa4.08MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.154 mg/mLALOGPS
logP2.28ALOGPS
logP1.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.47ChemAxon
pKa (Strongest Basic)0.47ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity88.62 m3·mol-1ChemAxon
Polarizability34.25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Laura Coppi, “Crystalline forms of meloxicam and processes for their preparation and interconversion.” U.S. Patent US20030109701, issued June 12, 2003.

US20030109701
General ReferencesNot Available
External Links
ATC CodesM01AC06M01AC56
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (45.4 KB)
MSDSDownload (35.7 KB)
Interactions
Drug Interactions
Drug
AbciximabMeloxicam may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Meloxicam can be increased when it is combined with Abiraterone.
AcebutololMeloxicam may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Aceclofenac.
AcenocoumarolMeloxicam may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Meloxicam.
Alendronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.
AliskirenMeloxicam may decrease the antihypertensive activities of Aliskiren.
AlprenololMeloxicam may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Meloxicam.
AmikacinMeloxicam may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMeloxicam may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Meloxicam can be decreased when combined with Amiodarone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Meloxicam.
AncrodMeloxicam may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.
Antithrombin III humanMeloxicam may increase the anticoagulant activities of Antithrombin III human.
ApixabanMeloxicam may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Meloxicam is combined with Apremilast.
AprepitantThe serum concentration of Meloxicam can be increased when it is combined with Aprepitant.
ArdeparinMeloxicam may increase the anticoagulant activities of Ardeparin.
ArgatrobanMeloxicam may increase the anticoagulant activities of Argatroban.
ArotinololMeloxicam may decrease the antihypertensive activities of Arotinolol.
AtazanavirThe metabolism of Meloxicam can be decreased when combined with Atazanavir.
AtenololMeloxicam may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Meloxicam can be decreased when combined with Atomoxetine.
AzapropazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.
BalsalazideMeloxicam may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Meloxicam.
BecaplerminMeloxicam may increase the anticoagulant activities of Becaplermin.
BefunololMeloxicam may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Meloxicam.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.
BenoxaprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Benoxaprofen.
BetaxololMeloxicam may decrease the antihypertensive activities of Betaxolol.
BevantololMeloxicam may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Meloxicam can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meloxicam.
BisoprololMeloxicam may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMeloxicam may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Meloxicam can be decreased when combined with Boceprevir.
BopindololMeloxicam may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Meloxicam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Meloxicam can be decreased when it is combined with Bosentan.
BromfenacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bromfenac.
BufuralolMeloxicam may decrease the antihypertensive activities of Bufuralol.
BumetanideMeloxicam may decrease the diuretic activities of Bumetanide.
BupranololMeloxicam may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Meloxicam.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meloxicam.
CapecitabineThe metabolism of Meloxicam can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Meloxicam.
CarbamazepineThe metabolism of Meloxicam can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meloxicam.
CarprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Carprofen.
CarteololMeloxicam may decrease the antihypertensive activities of Carteolol.
CarvedilolMeloxicam may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meloxicam.
CeliprololMeloxicam may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Meloxicam can be increased when it is combined with Ceritinib.
CertoparinMeloxicam may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meloxicam.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meloxicam.
CholecalciferolThe metabolism of Meloxicam can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meloxicam.
Citric AcidMeloxicam may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Meloxicam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Meloxicam can be decreased when combined with Clemastine.
ClodronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clonixin.
ClopidogrelThe metabolism of Meloxicam can be decreased when combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meloxicam.
ClotrimazoleThe metabolism of Meloxicam can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Meloxicam can be decreased when combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Meloxicam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Meloxicam can be decreased when combined with Crizotinib.
CyclosporineMeloxicam may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Meloxicam can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Meloxicam is combined with D-Limonene.
Dabigatran etexilateMeloxicam may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.
DalteparinMeloxicam may increase the anticoagulant activities of Dalteparin.
DanaparoidMeloxicam may increase the anticoagulant activities of Danaparoid.
DarunavirThe metabolism of Meloxicam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Meloxicam can be increased when it is combined with Dasatinib.
DaunorubicinMeloxicam may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Meloxicam can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deferasirox.
DelavirdineThe metabolism of Meloxicam can be decreased when combined with Delavirdine.
DesirudinMeloxicam may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.
DexamethasoneThe serum concentration of Meloxicam can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meloxicam.
DextranMeloxicam may increase the anticoagulant activities of Dextran.
Dextran 40Meloxicam may increase the anticoagulant activities of Dextran 40.
Dextran 70Meloxicam may increase the anticoagulant activities of Dextran 70.
Dextran 75Meloxicam may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meloxicam.
DicoumarolMeloxicam may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Meloxicam is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meloxicam.
DihydroergotamineThe metabolism of Meloxicam can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinMeloxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Meloxicam can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meloxicam.
DoxorubicinMeloxicam may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Meloxicam can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Meloxicam can be decreased when combined with Dronedarone.
DrospirenoneMeloxicam may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Droxicam.
Edetic AcidMeloxicam may increase the anticoagulant activities of Edetic Acid.
EdoxabanMeloxicam may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Meloxicam can be decreased when it is combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Meloxicam.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Meloxicam.
EnoxaparinMeloxicam may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Meloxicam is combined with Epirizole.
EpirubicinMeloxicam may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMeloxicam may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meloxicam.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meloxicam.
ErythromycinThe metabolism of Meloxicam can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Meloxicam can be decreased when it is combined with Eslicarbazepine acetate.
EsmololMeloxicam may decrease the antihypertensive activities of Esmolol.
Etacrynic acidMeloxicam may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Meloxicam.
Ethyl biscoumacetateMeloxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Meloxicam.
EtofenamateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.
EtravirineThe serum concentration of Meloxicam can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Meloxicam is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Meloxicam is combined with exisulind.
FelodipineThe metabolism of Meloxicam can be decreased when combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meloxicam.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Meloxicam.
FloxuridineThe metabolism of Meloxicam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Meloxicam can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flunixin.
FluorouracilThe metabolism of Meloxicam can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meloxicam.
FluvastatinThe metabolism of Meloxicam can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Meloxicam can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meloxicam.
Fondaparinux sodiumMeloxicam may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Meloxicam.
FosamprenavirThe metabolism of Meloxicam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Meloxicam can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meloxicam.
FosphenytoinThe metabolism of Meloxicam can be increased when combined with Fosphenytoin.
FramycetinMeloxicam may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMeloxicam may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Meloxicam can be increased when it is combined with Fusidic Acid.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Meloxicam.
GemfibrozilThe metabolism of Meloxicam can be decreased when combined with Gemfibrozil.
GentamicinMeloxicam may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
HeparinMeloxicam may increase the anticoagulant activities of Heparin.
HirulogMeloxicam may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Meloxicam is combined with HMPL-004.
HydralazineMeloxicam may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meloxicam.
Hygromycin BMeloxicam may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Meloxicam is combined with Icatibant.
IdarubicinMeloxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Meloxicam can be increased when it is combined with Idelalisib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meloxicam.
ImatinibThe metabolism of Meloxicam can be decreased when combined with Imatinib.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.
IndenololMeloxicam may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Meloxicam can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.
IndoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meloxicam.
IsavuconazoniumThe metabolism of Meloxicam can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Isoxicam.
IsradipineThe metabolism of Meloxicam can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Meloxicam can be increased when it is combined with Ivacaftor.
KanamycinMeloxicam may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Kebuzone.
KetoconazoleThe metabolism of Meloxicam can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.
LabetalolMeloxicam may decrease the antihypertensive activities of Labetalol.
LapatinibThe metabolism of Meloxicam can be decreased when combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Leflunomide.
LepirudinMeloxicam may increase the anticoagulant activities of Lepirudin.
LevobunololMeloxicam may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Meloxicam.
LithiumThe serum concentration of Lithium can be increased when it is combined with Meloxicam.
LopinavirThe metabolism of Meloxicam can be decreased when combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Meloxicam.
LovastatinThe metabolism of Meloxicam can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meloxicam.
LuliconazoleThe serum concentration of Meloxicam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Meloxicam can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meloxicam.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meloxicam.
MesalazineMeloxicam may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Meloxicam.
MetamizoleThe risk or severity of adverse effects can be increased when Meloxicam is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meloxicam.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.
MetipranololMeloxicam may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.
MetoprololMeloxicam may decrease the antihypertensive activities of Metoprolol.
MetrizamideMeloxicam may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe metabolism of Meloxicam can be decreased when combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meloxicam.
MitotaneThe serum concentration of Meloxicam can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Meloxicam can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Meloxicam.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meloxicam.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meloxicam.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Meloxicam.
NadololMeloxicam may decrease the antihypertensive activities of Nadolol.
NadroparinMeloxicam may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Meloxicam can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Meloxicam.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Meloxicam.
NCX 4016The risk or severity of adverse effects can be increased when Meloxicam is combined with NCX 4016.
NefazodoneThe metabolism of Meloxicam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Meloxicam can be decreased when combined with Nelfinavir.
NeomycinMeloxicam may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nepafenac.
NetilmicinMeloxicam may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Meloxicam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Meloxicam can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Meloxicam can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic Acid.
NilotinibThe metabolism of Meloxicam can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.
OlaparibThe metabolism of Meloxicam can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meloxicam.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.
OlsalazineMeloxicam may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meloxicam.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Meloxicam.
OmeprazoleThe metabolism of Meloxicam can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Orgotein.
OsimertinibThe serum concentration of Meloxicam can be increased when it is combined with Osimertinib.
OtamixabanMeloxicam may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.
OxprenololMeloxicam may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone.
PalbociclibThe serum concentration of Meloxicam can be increased when it is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Parecoxib.
ParomomycinMeloxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololMeloxicam may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Meloxicam can be increased when combined with Pentobarbital.
Pentosan PolysulfateMeloxicam may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Meloxicam.
PhenindioneMeloxicam may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Meloxicam can be increased when combined with Phenobarbital.
PhenprocoumonMeloxicam may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meloxicam.
PhenytoinThe metabolism of Meloxicam can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meloxicam.
PindololMeloxicam may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Meloxicam can be decreased when combined with Pioglitazone.
PiretanideMeloxicam may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.
PlicamycinMeloxicam may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Polystyrene sulfonate.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meloxicam.
PosaconazoleThe metabolism of Meloxicam can be decreased when combined with Posaconazole.
PractololMeloxicam may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Meloxicam.
PrimidoneThe metabolism of Meloxicam can be increased when combined with Primidone.
ProbenecidThe serum concentration of Meloxicam can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Propacetamol.
PropranololMeloxicam may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Meloxicam.
Protein CMeloxicam may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMeloxicam may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Meloxicam is combined with PTC299.
PuromycinMeloxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Meloxicam can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Meloxicam.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meloxicam.
QuinineThe metabolism of Meloxicam can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Meloxicam can be decreased when combined with Rabeprazole.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Meloxicam.
RanolazineThe metabolism of Meloxicam can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meloxicam.
ResveratrolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.
ReviparinMeloxicam may increase the anticoagulant activities of Reviparin.
RibostamycinMeloxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Meloxicam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Meloxicam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Meloxicam can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.
RitonavirThe metabolism of Meloxicam can be decreased when combined with Ritonavir.
RivaroxabanMeloxicam may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Meloxicam.
RosiglitazoneThe metabolism of Meloxicam can be decreased when combined with Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meloxicam.
SaquinavirThe metabolism of Meloxicam can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Meloxicam.
SecobarbitalThe metabolism of Meloxicam can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Meloxicam is combined with Seratrodast.
SildenafilThe metabolism of Meloxicam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Meloxicam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Meloxicam can be increased when it is combined with Simeprevir.
SorafenibThe metabolism of Meloxicam can be decreased when combined with Sorafenib.
SotalolMeloxicam may decrease the antihypertensive activities of Sotalol.
SpectinomycinMeloxicam may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Meloxicam.
SpironolactoneMeloxicam may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Meloxicam is combined with SRT501.
St. John's WortThe serum concentration of Meloxicam can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Meloxicam can be increased when it is combined with Stiripentol.
StreptomycinMeloxicam may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMeloxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Meloxicam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Meloxicam can be decreased when combined with Sulfamethoxazole.
SulfasalazineMeloxicam may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meloxicam.
SulfisoxazoleThe metabolism of Meloxicam can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Meloxicam.
SulodexideMeloxicam may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.
TacrolimusMeloxicam may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Meloxicam.
TamoxifenThe metabolism of Meloxicam can be decreased when combined with Tamoxifen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meloxicam.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Meloxicam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Meloxicam can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meloxicam.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Meloxicam.
TenofovirThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meloxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Meloxicam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Meloxicam can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiludronate.
TimololMeloxicam may decrease the antihypertensive activities of Timolol.
TobramycinMeloxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Meloxicam can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Meloxicam can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.
TorasemideMeloxicam may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Meloxicam.
TranilastThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.
TriamtereneMeloxicam may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.
TrimethoprimThe metabolism of Meloxicam can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Meloxicam.
Valproic AcidThe metabolism of Meloxicam can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Meloxicam.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Meloxicam.
VenlafaxineThe metabolism of Meloxicam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Meloxicam can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Meloxicam can be increased when it is combined with Voriconazole.
WarfarinMeloxicam may increase the anticoagulant activities of Warfarin.
XimelagatranMeloxicam may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Meloxicam can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Meloxicam.
ZiprasidoneThe metabolism of Meloxicam can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zomepirac.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Poulsen Nautrup B, Horstermann D: [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100. [PubMed:10220944 ]
  2. Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999 May;65(5):533-44. [PubMed:10340919 ]
  3. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  4. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [PubMed:10381787 ]
  5. Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension. 1999 Nov;34(5):1163-7. [PubMed:10567199 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  2. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [PubMed:10381787 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. [PubMed:9493314 ]
  2. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. [PubMed:9493314 ]
  2. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function:
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name:
PGD
Uniprot ID:
P52209
Molecular Weight:
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T: Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96. Epub 2007 Oct 16. [PubMed:17939016 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:31